Background
Phase III, non-inferiority RCT. 891 patients with clinical T1-2 N0 breast cancer undergoing breast-conserving surgery (BCS) who had 1 or 2 positive sentinel lymph nodes (SLNB). All patients received whole-breast irradiation (WBI) and systemic therapy. Randomized to ALND (removal of level I/II axillary nodes) vs SLNB alone (no further axillary surgery). Testing whether ALND could be safely omitted in low-volume axillary disease.
Interventions and follow up
Arm A: Sentinel lymph node biopsy (SLNB) alone — no further axillary surgery
Arm B: Axillary lymph node dissection (ALND) of level I/II axillary nodes
Primary endpoint: Overall survival (OS, non-inferiority)
mFollow up: 9.25 years
Arm B: Axillary lymph node dissection (ALND) of level I/II axillary nodes
Primary endpoint: Overall survival (OS, non-inferiority)
mFollow up: 9.25 years
Results
OS (10-yr): 86.3% vs 83.6% (SLNB vs ALND), HR 0.85, 95% CI 0.62–1.17 — non-inferior
DFS (10-yr): 80.2% vs 78.2%, HR 0.85, 95% CI 0.65–1.11
Locoregional recurrence: 5-yr rates 0.9% vs 0.5% — not significantly different
DFS (10-yr): 80.2% vs 78.2%, HR 0.85, 95% CI 0.65–1.11
Locoregional recurrence: 5-yr rates 0.9% vs 0.5% — not significantly different
Adverse events
Lymphedema: 13% vs 6% at 1 year (ALND vs SLNB).
Neurologic/functional: Axillary sensory loss and restricted shoulder motion higher in the ALND arm.
Surgical: Surgical complications substantially lower with SLNB alone; no significant difference in infection or seroma at 30 days.
Neurologic/functional: Axillary sensory loss and restricted shoulder motion higher in the ALND arm.
Surgical: Surgical complications substantially lower with SLNB alone; no significant difference in infection or seroma at 30 days.
Conclusions
SLNB alone was non-inferior to ALND for OS and DFS in patients with 1–2 positive sentinel nodes undergoing BCS with whole-breast irradiation. ACOSOG Z0011 fundamentally changed axillary surgical management for early breast cancer and dramatically reduced the use of ALND in this setting.
Key Limitations
Population strictly defined — BCS patients only with ≤2 positive sentinel nodes receiving WBI; does not apply to mastectomy patients, ≥3 positive nodes, or patients not receiving WBI. Tangential RT fields used in Z0011 may have irradiated the low axilla in the SLNB arm (providing inadvertent treatment), potentially explaining equivalent locoregional control. ALND arm had lower-than-expected recurrence rates, limiting power to detect differences. Long-term lymphedema data favor SLNB but are partially confounded by systemic therapy changes over time.
Clinical Context
ACOSOG Z0011 is one of the most practice-changing surgical oncology trials in breast cancer, reducing ALND rates in eligible patients by >80% in many centers. SLNB alone is the standard of care for T1-2 N0 breast cancer patients with 1–2 positive SLNs undergoing BCS + WBI. The SENOMAC trial (2023) extended this principle to patients undergoing mastectomy. ESMO-MCBS score: N/A (surgical non-inferiority trial).